Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or clinical decision-making. However, concerns over the credibility of real-world evidence studies have led to calls for more transparency on the design and conduct of RWE studies.
A joint task force between ISPE and ISPOR created a harmonized protocol template for RWE studies that evaluate a treatment effect and are intended to inform decision-making. The HARPER template provides clarity, structure, and a common denominator regarding the level of operational detail, context, and rationale necessary in a protocol.
HARPER = HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects
Link: https://lnkd.in/erkyU2iT
Four protocol templates were identified for RWE studies:
1. The European Medicines Agency’s (EMA) Guideline on Good Pharmacovigilance Practices (GVP) Module VIII – post-authorizations safety studies (PASS) template,
2. ISPE’s guidelines for good pharmacoepidemiology practice (ISPE GPP) section on protocol development,
3. The National Evaluation System for health Technology (NEST) protocol guidance, and
4. The Structured Template and Reporting Tool for Real World Evidence (STaRT-RWE).
The HARPER protocol contains nine sections, including a title page, abstract, and a table for amendments and updates. Each section includes structured free text, a structured table, or a figure, and a free-text section to lay out context and rationale for scientific choices.
The study design diagram shows the context and rationale for the study setting, time 0 (index date), inclusion criteria, exclusion criteria, variables, exposure, outcome, follow up, covariates, sensitivity analyses, data sources, metadata, and software used in the study.
The data sources section includes a free text component followed by a structured table for specifying data sources. The data sources section can also include a detailed evaluation of the fitness-for-purpose of data source options.
Overall, the HARPER framework is a valuable resource for researchers and clinicians who are planning or conducting RWE studies. The framework can help to ensure that protocols are well-designed and will produce high-quality evidence.
Share this story...
Real World Evidence (RWE) 101 – Parkinson’s Disease
RWE 101 - Parkinson’s Disease Real-world evidence (RWE) refers to clinical evidence regarding the usage and potential benefits or risks of a treatment derived from analysis of real-world data [...]
Real World Evidence (RWE) 101 – Benefits of RWE in the Context of Rare Diseases
RWE 101 - Benefits of RWE in the Context of Rare Diseases Real-world evidence (RWE) refers to information on health care that comes from real-world settings, such as electronic [...]
Real World Evidence (RWE) 101 – Disease Prevalence vs Incidence
RWE 101 - Disease Prevalence vs Incidence Real-world evidence (RWE), derived from real-world data (RWD), allows us to gain insights into disease prevalence and incidence outside of controlled clinical [...]
Real World Evidence (RWE) 101 – Principles for Ensuring that Research Results are Reliable, Valid, and Objective
RWE 101 - Principles for Ensuring that Research Results are Reliable, Valid, and Objective Ensuring that research results are reliable, valid, and objective requires careful planning, execution, and evaluation. [...]
Real World Evidence (RWE) 101 – Why Should Non-Interventional Studies NOT be Promotional?
RWE 101 - Why Should Non-Interventional Studies NOT be Promotional? Non-interventional studies (NIS) are designed to observe and analyze data from real-world clinical settings without intervening or manipulating any [...]
Real World Evidence (RWE) 101 – Seeding Studies
RWE 101 - Seeding Studies Seeding studies, in the context of real-world evidence (RWE), refer to studies that were conducted by pharmaceutical or medical device companies after a product's [...]







